Predictive Oncology (Predictive Oncology) Risk Assessment

View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Predictive Oncology is: High Risk: High uncertainty.

Competitive Comparison of Predictive Oncology's Risk Assessment

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Predictive Oncology's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Risk Assessment falls into.

Predictive Oncology (NAS:POAI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Predictive Oncology Risk Assessment Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Oncology (Predictive Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Executives

Robert L Myers	officer: CHIEF FINANCIAL OFFICER	4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr	director	633 1ST STREET WEST, SONOMA CA 95476
Veena Rao	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr	director	1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch	director	P O BOX 1572, PEPPERELL MA 01463
Pamela Bush	officer: Chief Business Officer	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley	director	1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith	director	151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle	director	1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz	10 percent owner	20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel	director	900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121